NLS iconovo

Iconovo has received a grant of USD 883,800 from the Bill & Melinda Gates Foundation. The grant work plan is focused on the development of a low-cost device that can provide delivery of medical compounds to the full (upper and lower) respiratory tract and will be performed in the period August 2022 – June 2023. […]

The Issue was subscribed for by several new Swedish and international institutional investors, such as Alcur Fonder, FE Fonder and Humle Fonder, as well as several existing owners, such as Andra AP-fonden, Fjärde AP-fonden, Handelsbanken Fonder and Länsförsäkringar Fondförvaltning AB. The company intends to use the proceeds from the Issue for accelerating and value-creational development […]

The expanded collaboration will include additional territories that lead to the announced potential for future annual royalty income more than doubling to USD 13.2 – 26.4 million. Iconovo and Amneal develop a generic Symbicort in the inhaler ICOres. The project is now entering the final phase, and Amneal has begun the set-up of commercial manufacturing […]

Iconovo has signed a development agreement with Monash University for the development of inhaled oxytocin in ICOone for maternal health. The agreement verifies the suitability of ICOone for use with innovative pharmaceuticals. Monash University’s Institute of Pharmaceutical Sciences (MIPS) is leading the development project supported by a research agreement with Janssen Pharmaceutica N.V., part of […]

Iconovo and its project “ICOone for inhaled vaccines” is the winner of the Lund University Innovation Award. The winning project was “ICOone for inhaled vaccines”. Vaccines are currently administered as injections, which in addition to the associated discomfort, also presents a variety of other challenges. One major problem with needles is that they are dangerous to […]